Since 2002, Lilly Ventures has
focused its investments in
great companies with
compelling life science
innovations that have the
potential to create a
pipeline of life-changing
medicines. We partner actively
with our portfolio company
management teams and
provide intellectual, as
well as financial, resources
to accelerate the path to
success.
Our collaborative partnership
leverages the collective
experience, deep expertise,
and networks of our
investment professionals for
the benefit of our portfolio
companies.
Forma Therapeutics Appoints Two New Vice Presidents to Lead Key Organizational Functions
view full storyKymera Therapeutics Appoints Biopharma Veterans Pamela Esposito and Jeff Albers to its Board of Directors
view full storyForma Therapeutics Appoints Biopharma Veteran Thomas G. Wiggans To Board Of Directors
view full storyNimbus Therapeutics Appoints Veteran Pharmaceutical Chemist Scott Edmondson, Ph.D., as Senior Vice President, Head of Chemistry
view full storyKymera Therapeutics Appoints Dr. Richard Chesworth as Chief Scientific Officer
view full storyKymera Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
view full storyProtagonist Appoints Sarah O’Dowd to Board of Directors
view full storyForma Therapeutics Elects Distinguished Researcher And Physician Wayne A.I. Frederick, M.D., To Board Of Directors
view full storyKymera Therapeutics and Sanofi Enter into Strategic Partnership to Advance Novel Protein Degrader Therapies to Patients
view full storyForma Therapeutics Announces Closing Of Initial Public Offering And Exercise In Full Of The Underwriters’ Option To Purchase Additional Shares
view full storyNimbus Therapeutics Presents Data on Novel HPK1 Inhibitor, Demonstrating Robust Inhibition of Tumor Growth In Vivo
view full storyHepcidin Mimetic PTG-300 Receives U.S. FDA Orphan Drug Designation for the Treatment of Polycythemia Vera
view full storyForma Therapeutics Presents Safety, Pharmacokinetic And Pharmacodynamic Data From Phase 1 Clinical Trial For Investigational Agent FT-4202 In Patients With Sickle Cell Disease
view full storyNimbus Therapeutics Announces Expansion of its Drug Discovery Pipeline Across Oncology, Immunology and Metabolism
view full storyKymera Therapeutics Initiates Enrollment in Non-Interventional Trial Evaluating IRAK4 Role in Patients with Hidradenitis Suppurativa and Atopic Dermatitis
view full storyAeglea BioTherapeutics Announces 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of Neurology
view full storySurface Oncology and Merck to Collaborate on Immuno-Oncology Study Evaluating SRF617, Targeting CD39 in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumor Patients
view full storySurface Oncology to Present Preclinical Data for Multiple Product Programs at the American Association for Cancer Research Annual Meeting
view full storyNimbus Therapeutics Announces Identification of a Potent, Selective HPK1 Inhibitor with Robust In Vivo Activity
view full storyProtagonist Therapeutics Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera
view full storyForma Therapeutics Appoints David N. Cook, Ph.D., To Chief Scientific Officer
view full storySurface Oncology Announces First Patient Dosed in Clinical Trial of Immuno-Oncology Antibody SRF388
view full storyForma Therapeutics Announces Preclinical Data Demonstrating Antitumor Activity Of A Potent And Selective Inhibitor Of CBP/P300 For Androgen Receptor Positive Cancers To Be Presented At The American Association For Cancer Research
view full storyFORMA Therapeutics Receives FDA Orphan Drug Designation For FT-4202 For The Treatment Of Sickle Cell Disease
view full storyAeglea BioTherapeutics Announces Approval of Clinical Trial Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)
view full storySurface Oncology Announces First Patient Dosed in Clinical Trial of Immuno-Oncology Candidate SRF617
view full storySutro Biopharma Announces Extension of First Cytokine Derivative Research Program Under Collaboration with Merck
view full storyKymera Therapeutics Announces $102 Million Series C Financing to Advance its Protein Degrader Pipeline and Platform
view full storyFORMA Therapeutics Announces FT-4202 Granted Fast Track Designation And Rare Pediatric Disease Designation For Treatment Of Sickle Cell Disease
view full storyMycovia Pharmaceuticals Initiates Extension Clinical Studies to Further Evaluate Long-Term Efficacy of Oteseconazole (VT-1161) in Patients with Recurrent Vulvovaginal Candidiasis
view full storyFORMA Reports Achievement Of Early-Stage Clinical Development Milestones For Assets Licensed Exclusively To Boehringer Ingelheim And Bristol-Myers Squibb
view full storyAeglea BioTherapeutics Submits CTA Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)
view full storyProtagonist Therapeutics Achieves Milestone in Janssen Biotech, Inc., Collaboration
view full storyProtagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Hereditary Hemochromatosis
view full story